第79回_プログラム.indd
|
|
- さゆり しげい
- 7 years ago
- Views:
Transcription
1
2
3
4
5
6
7
8 Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 MEMO
OM_J_MFS2B_3.5B_body_CS_151023N.indd
1 2 13 14 25 26 3 15 27 4 5 16 17 28 6 18 7 8 19 20 9 21 10 11 22 23 12 24 1. 2. 5. 3. 4. !!! 1. 2. 1. 2. 1. !!!! 1. 2. 1. 1. 2. 3.! 1. 2. 3. !! !!!! 1. 2. 1. 2. 1. !!!!! 1. 1. 1.! 1. 2. 3. 1. 1. 2.!
More information7310_J_Print.qxd
J 1 2 3 4 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 1 2 3 1 2 3 1 2 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 1 2 1 2 1 2 1 2 3 1 2 3 1 1 2 2 1 2 3 4 1 H P C 1 2 3 4 1 2 1 2 1 2 1 2 3 4 1
More information1
1 3 2 5 4 7 6 8 9 11 10 12 13 14 15 16 17 19 18 20 21 23 22 25 24 27 26 29 28 31 30 33 32 35 34 37 36 39 38 40 41 43 42 45 44 46 47 49 48 51 50 52 53 55 54 57 56 59 58 60 61 63 62 64 65 67 66 68 69 70
More information2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71
More information2
2 ... 4... 4... 6... 8... 10... 12... 14... 19... 21... 23... 28... 30... 31... 31... 31... 32... 33... 34... 35... 36... 37... 39... 48... 50... 52 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
More information患者用冊子160524.indd
2 ... 4... 4... 6... 8... 10... 12... 14... 16... 21... 23... 25... 30... 32... 33... 33... 33... 34... 35... 36... 37... 38... 40... 41... 43... 48... 50... 58 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
More informationindd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
More information総合補償保険(普通傷害保険)ご契約のしおり
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 0120-25-7474 27 28 29 1170 33192 33128 37152 28245 1473 57 80 30 31 3510565 32 180 32 32 180 33 180 181 13 180 180 104 11 34 180 10
More information<個人用>賠償責任保険ご契約のしおり
1 2 3 4 5 6 7 8 9 10 11 12 0120-25-7474 13 12 14 23 23 15 26 17 17 17 16 13 17 12 14 10 1618 15 1015 16 18 12 18 30 180 90 120 22118 60 180 24205 19 27 7 10 15 15 1 25 2 35 3 45 4 55 5 65 6 70 7 75 8 80
More information普通傷害保険ご契約のしおり
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 0120-25-7474 22 23 24 25 1170 33192 33128 37152 28245 1473 57 80 26 27 3510565 28 180 32 32 180 29 180 181 13 180 180 104 11 30 180 10 90 180 31 32
More information森林火災保険ご契約のしおり
1 0120-25-7474 2 20 3 50 50 50 20 20 80 1 4 30 125cc 5 500 30 10 20 20 300 72 301,000 6 19 7 19 19 14 32 12 8 13 15 16 16 1820 17 20 9 26 30 180 90 22118 60 180 24205 28 80 10 500 500 500 20 20 20 300
More information京都造形芸術大学 大学院 芸術研究科(通信教育)芸術環境専攻 修士課程 学生募集要項2017
1. 2. 3. index 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 1 1 2 3 4 2 5 3 6 7 5 7 8 4 8 5 9 6 10 1 5 7 8 11 9 12 10 1 2 11 12 5 13 14 15 3 4 16 17 5 18 19 20 4 21 1 22 2 23 3 8
More informationJACD UPDATED onmar.31,
JACD... 2... 3... 11... 14... 17... 19 UPDATED onmar.31, 2014 1 JACD UPDATED onmar.31, 2014 2 JACD UPDATED onmar.31, 2014 3 JACD UPDATED onmar.31, 2014 4 JACD UPDATED onmar.31, 2014 5 JACD UPDATED onmar.31,
More informationスライド 1
1 1520 12 31 1521 31 1620 12 31 11 1621 31 11 15 1 1 20 12 3110 7 3 21 1 1 20 15 5 20 15 5 15 120 12 20 7 3 Nasdaq 2 3 15 16 17 18 40 30 40 10 100 40 60 30 30 30 0 0 0 10 15 13 9 30 15 22 12 31 13 10 1
More informationMELSEC-Qシリーズ クイックスタートガイド
P oint 1 2 3 4 5 6 7 8 9 P oint 10 11 12 P oint 1. 2. 3. 4. P oint 13 1. 14 2. 15 16 1. 4. 2. 3. 5. 17 7. 6. P oint 18 19 20 P oint P oint 21 22 1. 23 2. 1. 2. 3. 24 1. 2. 3. 4. P oint 25 26 P oint 27
More informationVENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
More informationTitle 骨量規定転写因子シュニュリ3の新規標的遺伝子同定と機能解析 Author(s) 石堂, 康弘 Citation Issue Date 2014-06-27 URL http://hdl.handle.net/10232/24125 http://ir.kagoshima-u.ac.jp adult (Schnurri, Shn)3/Hivep3 Runx2 Shn/Hivep Shn3
More information1) Roth, J., Glick, S. M., Yalow, R. S. and Berson, S. A.: Hypoglycemia: A potent stimulus to secretion of growth hormone. Science, 140, 987-988, 1963. 2) Ogawa, N.: Routine Ultramicro-Measurement of Human
More informationサイトメトリー12-1.indd
Cell Growth Inhibition and Apoptosis in Cancer Cells Kazuki Omoteyama, Shoichi Inoue and Alaa-eldin Salah-eldin Department of Environmental Medicine and Informatics, Graduate School of Environmental Earth
More informationRinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
More informationuntitled
1 4 4 6 8 10 30 13 14 16 16 17 18 19 19 96 21 23 24 3 27 27 4 27 128 24 4 1 50 by ( 30 30 200 30 30 24 4 TOP 10 2012 8 22 3 1 7 1,000 100 30 26 3 140 21 60 98 88,000 96 3 5 29 300 21 21 11 21
More information橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
More informationスライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
More information2
2 3 4 5 6 7 8 9 1 2 3 4 5 10 11 12 1 2 1 2 1 2 13 14 3 17 15 1 2 3 D Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression level in non-small cell lung cancer a preliminary
More informationh1_h4_修正B.ai
Ver.1.0 CONTENTSQ1 Q1-1 MEMO MEMO MEMO MEMO MEMO Q1-2 MEMO MEMO Q3 Q3-1 Q3-2 Q3-3 Q2 Q2-1 Q2-2 Q2-3 Q4 Q4-1 Q4-2 Q4-3 Q5 Q5-1 Q6 Q6-1 Q6-2 Q10 MEMO Q7 Q7-1 MEMO MEMO Q8 Q8-1 MEMO Q9-1 MEMO Q9 MEMO Q11
More information01.浅野.ppt
2010 14 23 1 15 2010 the 74 th Annual Scientific Meeting of American College of Rheumatology November 7 11, 2010 at Georgia World Congress Center, Atlanta, GA, USA 2284 SSc 142 Plenary Session: 3 Concurrent
More informationCRPNo30表紙.ai
No.30 2012/6 20126 Clinical Research Professionals No.30 17 18 Clinical Research Professionals No.30 2012 6 20126 Clinical Research Professionals No.30 19 20 Clinical Research Professionals No.30 2012
More information50-3ガイド10ポ.indd
25 7 乳房専用 PET 診療ガイドライン作成メンバー PET 1 はじめに PET 18 F-2- -2- -D- FDG 14 12 FDG-PET FDG-PET 1) T1b 0.5 cm 1.0 cm T1c 1.0 cm 2.0 cm P=0.003 1.0 cm 2) MRI FDG-PET PET 1 cm FDG FDG 1 対向型乳房専用 PET 装置 2 2 3 6) 2 4
More information薬 理 学 教 室
業績目録 ( 平成 22 年 ) (B-a) 英文総説 1) Fan C, Katsuyama M, Wei H, Xia Q, Liu W, Yabe-Nishimura C. Molecular Mechanisms Underlying PGF2alpha-induced Hypertrophy of Vascular Smooth Muscle Cells. Yakugaku Zasshi
More information小児感染免疫第23巻第1号
Vol. 23No. 163 42 HPV HPV 1113 HPV 42 HPV HPV HPV 1 1 510 1020 HPV 1020 510 HIV 0.1 0.005 HIV 2030 HIV 0.2 510 HPV 1020 15 HIV 2030 HIV HIV 0.2 0.1 Takeyuki Sato 2608677 181 64 2011 2 1 1518 6,000 513
More informationTaketora
º Hospital Products 45 5 67 6 812 8 13 1415 1617 1820 21 2225 2627 2829 31 32 3335 3637 3741 4243 4663 4649 5051 5255 56 57 5861 62 63 6467 7077 7879 8084 80 81 8283 84 8691 92100 9293 94 95 9697 98 99
More information20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
More information< E D834F E696E6464>
EXTENSION EXTENSION PROGRAM 1 2 3 4 5 6 4 6 6 6 3 8 5 6 6 5 6 5 4 6 8 6 4 2 5 4 5 5 5 1 2 2 3 4 4 2 4 4 3 3 6 5 1 1 1 1 1 1 1 3 6 5 1 1 1 1 1 1 1 5 5 1 1 1 1 1 1 1 4 5
More information計算機生命科学の基礎II_
Ⅱ 1.4 atsushi_doi@cell-innovator.com 812-8582 3-1-1 8 806 http://www.cell-innovator.com BioGPS Connectivity Map The Cancer Genome Atlas (TCGA); cbioportal GO DAVID, GSEA WCGNA BioGPS http://biogps.org/
More information_統合化推進プログラム_金久チーム_サイトビジット資料
ライフサイエンスデータベース統合推進事業統合化推進プログラム ゲノム 疾患 医薬品のネットワークデータベース実施状況 京都大学化学研究所 金久 實 2018 年 8 月 22 日サイトビジット資料 KEGG NETWORK とは NAR DB Issue 2017 KEGG: new perspectives on genomes, pathways, diseases and drugs From
More information7th埼玉オープン.pm6
6 7 6 7 6-0 6 7 0 6-6 -0 7-0 -7 8 8 - - 9 0 0 - -8 9 0-6 -8 0 8- -7-6 6-0 -7 7 0 8-8 (by Mitsuhashi) 6 0- -8 6 7 8 6 7 9 0-8 8 9 0 7 6 8 9-8 6-8 0 7-7 - 8 9 0 - -0 7 6 6-7 - - - 9- -6 9 0 8-8 -0 - -7-7
More informationSTUDIES ON THE RELATION BETWEEN LATE DUMPING SYNDROME AND GLUCAGON RESPONCES TO GLUCOSE Taisuke MATSUI The First Department of Surgery, Nara Medical U
STUDIES ON THE RELATION BETWEEN LATE DUMPING SYNDROME AND GLUCAGON RESPONCES TO GLUCOSE Taisuke MATSUI The First Department of Surgery, Nara Medical University, Kashihara (Director: Prof. H. Nakano) This
More information学位論文の内容の要旨 論文提出者氏名 小川憲人 論文審査担当者 主査田中真二 副査北川昌伸 渡邉守 論文題目 Clinical significance of platelet derived growth factor -C and -D in gastric cancer ( 論文内容の要旨 )
学位論文の内容の要旨 論文提出者氏名 小川憲人 論文審査担当者 主査田中真二 副査北川昌伸 渡邉守 論文題目 Clinical significance of platelet derived growth factor -C and -D in gastric cancer ( 論文内容の要旨 ) < 要旨 > platelet derived growth factor (PDGF 血小板由来成長因子)-C,
More information1〜4
1 1875 1969 1985 2 1989 90 1990 91 1989 80 2000 3 4 5 1 1969 2 1995 3 2000 4 2000 5 2004 91 6 7 41 1908 1918 10 10 8 1934 15 9 10 6 2004 13 7 11 90 2004 240 8 9 1989 90 10 92 32 42 20 450 11 36 12 13 14
More informationMicrosoft Word - TIP2006-3-TGN doc
TIP 2006 3 Vol 21 No3 p21-24 TGN1412 I NPO 3 13 15 [1,2] I TGN1412 18 40 1 ICU 19 6 4 3 [3] The Medicines and Healthcare Products Regulatory Agency MHRA [2] TGN1412 TGN1412 CD28-SuperMAB T TGN1412 T superagonistic
More information5698-5701. 5) Kadowaki T, Tobe K, Honda-Yamamoto R, Tamemoto H, Kaburagi Y, Momomura K, et al.: Signal transduction mechanism of insulin and insulin-like growth factor-1. Endocrine J 1996; 43: 33-41. 6)
More information特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More informationGynecologic Oncology Trial and Investigation Consortium GOTIC-002
Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 3 8 ...2...2...2...2...3...4...4...5...9...9...9...9...9... 13... 13... 13... 13... 13... 13... 13... 14... 14... 15... 15... 15...
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
More information橡'98寺尾班報告書.PDF
(OHSS) interleukin-8 (IL -8) 33 histamine prostaglandin angiotensin 8 IL-8 OHSS 1 IL-8 23 Wistar rat pregnant mare serum gonadotropin 10 unit 48 human chorionic gonadotropin(hcg) 10 unit IL-8 0.2, 2.0,
More information8 20 symptom free 2 NEJM Clinical Practice fluticasone 1 2 fluticasone IgE 100U/ml 1819 Bostock 1 A Mycobacterium Toxoplasma
The Lancet, vol 378, Dec.17/24/31,2011 Alexander N Greiner USA Peter W Hellings, Guiseppina Rotiroti Glenis K Scadding The Lancet, Dec. 17/24/31, 2011 http://www.allergy.go.jp/allergy/guideline/04/index.html
More information好中球とPTX3
Neutrophils and pentraxin 3 Makoto Naito, Alexander S. Savchenko and Akira Inoue Pentraxin 3 (PTX3) is the first identified long pentraxin, and is rapidly produced and released by several cell types in
More informationTheme:譲渡担保
070805TOKYO TOKYOYOKOHAMAOSAKAKYOTONAGOYAFUKUOKA 1 CASE 1 2 3 CASE MEMO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42
More information日本消化器外科学会雑誌第30巻第3号
Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment
More informationⅡ Ⅲ Ⅳ Assertive community treatment - Issues from scientific and clinical literature with implications for practice The Impact of Supported Employment and Working on Clinical and
More information*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combinati
*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combination with angiotensin II induced hyperten sion chemotherapy
More informationJ Life Sci Res 2014; 12: Osaka Prefecture University Journal of Life Science Research Online ISSN
J Life Sci Res 2014; 12: 15-19 2014 Osaka Prefecture University Journal of Life Science Research Online ISSN 2186-5809 583-8555 3-7-30 577-8567 3-1-1 2014 9 11 2014 10 21 Exposure mild-level LED light
More informationPEANUTS 2014 Peanuts Worldwide 1 2 3 4 5 6 1 2 3 4 5 6 7 8 9 10 11 MEMO 12 1 2 3 4 MEMO 5 6 7 8 9 10 MEMO 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
More informationBiotinylated Kinases BTNABL(ABL1) Tyrosineprotein kinase ABL1 Biotinylated N 2 Nterminal DYKDDDDK カルタヘナ 80 BTNACTR2B(ACVR2B) Activin r
2. ビオチン化キナーゼタンパク質 Biotinylated Kinases 表面プラズモン共鳴 (SPR) やバイオレイヤー干渉法 (BLI) といった物質間の相互作用を評価する系 ( 解析機器 ) でご利用いただけるビオチン化キナーゼタンパク質を販売しております これらの解析機器で低分子化合物の創薬研究 開発を行なう際 リガンドとする標的分子蛋白質を活性 構造を保持したままセンサー表面に固定化
More information<2003年分東京医科歯科大学産科婦人科学教室業績>
1.Obayashi S, Aso T, Sato J, Hamasaki H, Azuma H: Intimal hyperplasia in human uterine arteries accompanied by impaired synergism between prostaglandin I2 and nitric oxide. British Journal of Pharmacology
More information摂食行動を制御する新しい脳内因子を発見 -食欲調節メカニズムの解明や 肥満対策の創薬への応用に期待-
CRH PVH DMH CCK LH α-msh (POMC) VMH ARC NPY AgRP Orexin MCH Bar = 5 μm Neurosecretory protein GL (NPGL) 1. vs BBRC (214) 2. 1 3. 4. M C SP NPGL 8aa C GLGKR ( ) C Cys 2 NPGL mrna/actb mrna 8 7 6 5 4 3
More information